A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.
Wainberg
Zev
Z
GI Oncology Program, David Geffen School of Medicine, University of California, Los Angeles 90095, USA.
Hecht
J Randolph
JR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D000077544:Panitumumab; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000068258:Bevacizumab; D000077544:Panitumumab